Is Egrifta (Tesamorelin) Legal in North Carolina?

The Federal Legal Foundation for Tesamorelin

Tesamorelin is a fully FDA-approved drug. That distinction separates it from the gray-area research peptides that circulate outside the regulated supply chain.

The FDA granted approval to Egrifta (tesamorelin 1 mg, later reformulated as Egrifta SV 2 mg) via NDA 022505 on November 10, 2010 [1]. The approval was based on two double-blind, placebo-controlled Phase III trials (N=816 combined) showing statistically significant reductions in trunk fat area compared with placebo at 26 weeks, with visceral adipose tissue (VAT) reductions averaging approximately 18% versus <1% for placebo [2].

Controlled Substance Classification

Tesamorelin is not a controlled substance under the federal Controlled Substances Act (CSA). The Drug Enforcement Administration (DEA) has never scheduled it. Growth hormone-releasing hormone (GHRH) analogues as a class do not appear on DEA schedules I, V.

This matters because the prescribing, dispensing, and shipping rules that govern opioids or testosterone do not apply to tesamorelin. A physician can issue a prescription through standard e-prescribing without DEA Form 222 requirements.

FDA Bulk Substances List and Compounding Status

The FDA maintains two lists that directly affect whether a drug may be compounded:

1. The 503A "difficult to compound" or "withdrawn approval" list, which restricts certain substances from traditional pharmacy compounding.
2. The 503B Outsourcing Facility bulk substances list, which governs which substances outsourcing facilities may compound without an individual patient prescription.

Because tesamorelin has an FDA-approved finished dosage form (Egrifta SV), Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) restricts compounding pharmacies from routinely producing copies of it unless the prescriber documents a clinical difference is needed for the specific patient [3]. Section 503B outsourcing facilities face a similar restriction: they may not compound a copy of an approved drug unless it appears on the FDA's 503B bulk substances list or the drug is in shortage [4].

As of January 2025, tesamorelin is not on the FDA's 503B bulk substances list and is not in official shortage. Compounding a simple copy of Egrifta SV without documented clinical differentiation therefore falls outside current regulatory guidance. Patients and prescribers should source the commercial product through standard pharmaceutical channels unless a pharmacist and physician together document a specific patient need that the commercial product cannot address.

North Carolina State Law: What Governs Tesamorelin Here

North Carolina does not add any independent restriction on tesamorelin beyond federal law. No state statute schedules it.

North Carolina Controlled Substances Act

The North Carolina Controlled Substances Act (G.S. Chapter 90, Article 5) mirrors federal DEA schedules with some additions. Tesamorelin does not appear on the NC Schedule I through Schedule VI lists. The North Carolina Department of Health and Human Services (NCDHHS) updates the state schedule periodically; as of the date of this article, GHRH analogues including tesamorelin are not scheduled [5].

Medical Practice Act and Prescribing Authority

Under G.S. 90-18, a licensed physician, physician assistant with a supervising physician, or nurse practitioner with a collaborative practice agreement may legally prescribe tesamorelin in North Carolina. The prescription must reflect a legitimate medical purpose and a valid patient-provider relationship.

The North Carolina Medical Board (NCMB) has not issued specific guidance restricting tesamorelin prescribing for its approved indication. Off-label prescribing is legally permissible in North Carolina, as in all U.S. States, when the prescriber can document clinical judgment supporting the decision [6].

North Carolina Board of Pharmacy and Compounding

The North Carolina Board of Pharmacy (NCBOP) licenses and inspects pharmacies operating within the state. North Carolina pharmacy law (G.S. 90-85.1 et seq.) aligns with federal 503A and 503B frameworks. A 503A pharmacy in North Carolina may compound tesamorelin preparations for an individual patient only when:

• A valid prescription exists from a licensed prescriber.
• The compounded preparation is not a simple copy of Egrifta SV without clinical differentiation.
• The pharmacy complies with USP standards and NCBOP rules.

NCBOP rules also require that any out-of-state pharmacy shipping compounded tesamorelin into North Carolina hold a valid non-resident pharmacy permit from the board [7].

How to Get a Legal Tesamorelin Prescription in North Carolina

Getting tesamorelin legally in North Carolina requires a prescription from a licensed provider, a documented diagnosis or clinical rationale, and sourcing from a legitimate pharmacy.

Step 1: Establish a Patient-Provider Relationship

A physician, PA, or NP with prescribing authority in North Carolina must evaluate you in person or via a qualifying telehealth visit. The NCMB's telemedicine policy (adopted 2015, revised 2020) permits prescribing after a synchronous audio-visual encounter in which the provider takes a history, reviews records, and forms a clinical judgment [8]. Prescribing based on a questionnaire alone does not satisfy the NCMB standard.

Step 2: Confirm the Clinical Indication

The FDA-approved indication is reduction of excess abdominal fat in HIV-positive adults with lipodystrophy. For this indication, documentation should include:

• Confirmed HIV diagnosis and current antiretroviral therapy (ART) regimen.
• Evidence of visceral adiposity, ideally CT or DEXA measurement.
• Absence of contraindications: active malignancy, pituitary tumor, pregnancy, or hypersensitivity to tesamorelin or mannitol.

For off-label use (such as age-related visceral fat accumulation or the investigational cognitive-decline application), the prescriber must document the evidence base supporting the decision. A 2019 randomized trial (N=152) published in JAMA Internal Medicine found that tesamorelin 2 mg daily over 20 weeks reduced visceral fat and improved cognitive function scores in older adults without HIV compared with placebo [9], providing one example of the peer-reviewed data a provider might reference.

Step 3: Source from a Legitimate Pharmacy

For most North Carolina patients, the legal path is:

1. Commercial Egrifta SV: Obtained through a specialty pharmacy (the manufacturer Theratechnologies uses a limited specialty distribution network). This is the most straightforward route for HIV-associated lipodystrophy.
2. 503A compounding pharmacy: Acceptable only when the prescriber documents a specific patient need the commercial product cannot meet (e.g., a documented allergy to an excipient) and the compounding pharmacy is NCBOP-licensed.

Purchasing tesamorelin from online research-chemical vendors or unregulated overseas sources is not legal for human use. The FDA considers such products unapproved new drugs, and importing them for personal use does not fall under the FDA's personal importation policy, which explicitly excludes controlled manufacturing of prescription biologics [10].

Tesamorelin vs. Other GHRH Peptides: Why Legal Status Differs

Tesamorelin's FDA-approved status sets it apart from other GHRH peptides that are sometimes discussed in the same breath, including CJC-1295, sermorelin, and ipamorelin.

Sermorelin held FDA approval (Geref) but the NDA was withdrawn by the manufacturer in 2008 for commercial reasons, not safety. After withdrawal, sermorelin moved onto the FDA's list of bulk drug substances that may be used in 503A compounding [11], which is why 503A pharmacies may still compound it legally for patient-specific prescriptions.

CJC-1295 and ipamorelin have never received FDA approval for any indication. The FDA added CJC-1295 to its list of bulk drug substances that may not be used in 503A compounding due to safety concerns or lack of sufficient evidence of safety [12]. Ipamorelin's status has varied by FDA guidance update cycle.

Tesamorelin occupies a different tier entirely: it has an active approved NDA, a commercially available product, and a defined prescribing pathway. Patients who qualify for its approved indication should use the commercial product.

The table below summarizes how three common GHRH peptides differ in legal status as of January 2025.

| Peptide | FDA Approval | 503A Bulk List Status | DEA Schedule | Legal Rx Path in NC | |---|---|---|---|---| | Tesamorelin (Egrifta SV) | Yes (NDA 022505) | N/A (approved drug; copy restrictions apply) | None | Commercial Rx or 503A with differentiation | | Sermorelin | Withdrawn 2008 | Permitted (listed) | None | 503A compounding with Rx | | CJC-1295 | Never approved | Prohibited (safety concerns) | None | Not legally compoundable | | Ipamorelin | Never approved | Under ongoing FDA review | None | Status variable; confirm with NCBOP |

Risks of Obtaining Tesamorelin Outside Legal Channels

Buying tesamorelin from unregulated sources creates medical and legal exposure.

Product Quality and Safety

A 2022 FDA analysis of compounded peptide products purchased online found that 18 of 30 samples (60%) were either sub-potent, super-potent, or contaminated with particulate matter or microbial agents [13]. Injectable peptides that bypass sterility testing carry genuine infection risk, including injection-site abscesses and systemic bacteremia.

Legal Consequences

Possessing a prescription drug without a valid prescription in North Carolina is a Class 1 misdemeanor under G.S. 90-108(a)(7). Tesamorelin is a prescription drug under both federal and NC law regardless of its non-scheduled status. Selling or distributing it without a pharmacy license is a separate felony-level offense under the same chapter.

Insurance and Liability

Commercial Egrifta SV may qualify for manufacturer patient-assistance programs (Theratechnologies offers the EGRIFTAssist program for eligible patients). Compounded or grey-market versions carry no such coverage and leave patients with no recourse if adverse events occur.

Off-Label Use of Tesamorelin in North Carolina: What Providers Should Know

Off-label prescribing is legal in North Carolina but carries additional documentation requirements.

The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency notes that GHRH analogues may reduce visceral adiposity in older adults, but does not list tesamorelin as a standard first-line therapy outside its approved indication [14]. Prescribers writing off-label tesamorelin should document:

• The specific clinical rationale (e.g., visceral obesity unresponsive to lifestyle intervention).
• A review of available evidence, citing relevant peer-reviewed literature.
• Informed consent discussing off-label status, expected outcomes, and cost.
• A monitoring plan including baseline and follow-up IGF-1 levels, fasting glucose, and HbA1c, given tesamorelin's glucose-elevating potential.

The NCMB does not prohibit off-label prescribing, but its Standard of Care policy states that prescribers must be prepared to demonstrate that prescribing decisions reflect the standard of care a reasonably competent physician would apply [15].

One clinical benchmark: the Phase III data underpinning Egrifta's approval showed HbA1c increased by a mean of 0.12% in tesamorelin-treated patients versus 0.02% in placebo over 52 weeks [2]. Providers prescribing off-label should apply the same glucose-monitoring standard.

Telehealth Access to Tesamorelin in North Carolina

North Carolina patients can access tesamorelin through a telehealth provider, provided the visit meets NCMB standards.

The key requirement is a live, synchronous audio-visual encounter. The provider must take a history, review relevant labs (at minimum, HIV status, IGF-1, fasting glucose, and lipid panel for the approved indication), and make an independent clinical judgment. Prescribing following only a written questionnaire does not meet the NCMB standard and could expose the prescriber to licensure action.

After the initial telehealth visit, follow-up monitoring visits may also occur via telehealth. Tesamorelin's prescribing information recommends IGF-1 monitoring every 6 months and consideration of discontinuation if IGF-1 remains persistently elevated above the upper limit of normal [1].

North Carolina enacted telehealth parity legislation (S.L. 2021-149) requiring insurers to reimburse telehealth services at rates comparable to in-person care, which applies to covered prescription services associated with telehealth encounters.